A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
2014年6月11日 更新者:Tibotec Pharmaceuticals, Ireland
A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
調査の概要
状態
完了
条件
詳細な説明
This is a randomized (the study medication is assigned by chance), active controlled (participants are assigned to either a recognized effective treatment or the study medication) study.
This study consists of 3 phases: screening phase (4 weeks), treatment phase (96 weeks), and follow up phase (4 weeks).
In the treatment phase, participants will be randomly assigned to 1 of the 4 treatment groups: (1) TMC278 25 mg, (2) TMC278 75 mg, (3) TMC278 150 mg, or (4) efavirnez (control group); along with investigator selected 2 non-nucleoside reverse transcriptase inhibitor (NRTIs) until Week 96.
TMC278 will be assigned by double-blinded fashion (participant and investigator are not aware of the TMC278 dose what participants will receive) and efavirnez will be assigned by open-label fashion (all people know what treatment participants will receive).
After Week 96, 3 optional open-label (all people know the identity of the intervention) extension periods will be conducted to collect long term safety and effectiveness data of TMC278.
3 optional extension periods are: first optional extension period (all participants will receive TMC278 75 mg + 2 NRTIs from Week 96 to Week144); second optional extension period (all participants will receive TMC278 25 mg + 2 NRTIs from Week 144 to Week 240); and third optional extension period (all participants will receive TMC278 25 mg + 2 NRTIs from Week 240 until TMC278 is commercially available).
Participants on efavirenz group will have the option to continue on efavirenz + 2 NRTIs until the total treatment duration of 240 weeks.
Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, physical examination, and vital signs which will be monitored throughout the study.
The maximum duration of the study will be 104, 152, or 248 weeks, plus the optional third extension period.
研究の種類
介入
入学 (実際)
368
段階
- フェーズ2
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
California
-
Beverly Hills、California、アメリカ
-
-
District of Columbia
-
Washington、District of Columbia、アメリカ
-
-
Florida
-
Orlando、Florida、アメリカ
-
Tampa、Florida、アメリカ
-
-
Georgia
-
Atlanta、Georgia、アメリカ
-
-
New York
-
Stony Brook、New York、アメリカ
-
-
North Carolina
-
Winston-Salem、North Carolina、アメリカ
-
-
Texas
-
Addison、Texas、アメリカ
-
-
Washington
-
Seattle、Washington、アメリカ
-
-
-
-
-
Buenos Aires、アルゼンチン
-
Rosario、アルゼンチン
-
-
-
-
-
London、イギリス
-
Manchester、イギリス
-
-
-
-
-
Kampala、ウガンダ
-
-
-
-
-
Wien、オーストリア
-
-
-
-
-
Bangkok、タイ
-
Chiang Mai、タイ
-
Khon Kaen、タイ
-
-
-
-
-
Berlin、ドイツ
-
Freiburg、ドイツ
-
Köln、ドイツ
-
München、ドイツ
-
-
-
-
-
Paris、フランス
-
Paris Cedex 10、フランス
-
Paris Cedex 12、フランス
-
Tourcoing、フランス
-
-
-
-
-
Campinas、ブラジル
-
Curitiba、ブラジル
-
Pinheiros、ブラジル
-
Rio De Janeiro、ブラジル
-
Sao Paulo、ブラジル
-
-
-
-
-
San Juan、プエルトリコ
-
-
-
-
-
Ciudad De Mexico、メキシコ
-
-
-
-
-
Kazan、ロシア連邦
-
Moscow、ロシア連邦
-
Moscow N/A、ロシア連邦
-
Nizhny Novgorod、ロシア連邦
-
Saint-Petersburg、ロシア連邦
-
St Petersburg、ロシア連邦
-
Volgograd、ロシア連邦
-
-
-
-
-
Beijing、中国
-
-
-
-
-
Bloemfontein、南アフリカ
-
Cape Town、南アフリカ
-
Johannesburg、南アフリカ
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Documented human immunodeficiency virus type 1 (HIV-1) infection
- Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or equal to 2 weeks treatment prior to screening with an nucleoside reverse transcriptase inhibitors
- HIV-1 plasma viral load above 5000 HIV-1 RNA copies per milliliter, at screening
- Cortisol of at least 550 nano moles per liter (19.9 microgram per deciliter) at screening
- Sensitivity to investigator selected nucleosides, at screening
Exclusion Criteria:
- Currently having active Acquired Immunodeficiency Syndrome (AIDS) defining illness
- Known or suspected acute (primary) HIV-1 infection
- Any current or history of adrenal disorder, and an acute hepatitis A, B, or C infection
- Documented genotypic evidence of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) resistance at screening
- Pregnant or breastfeeding females
- Not agree to protocol-defined effective use of contraception
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:TMC278 25 mg
Participants will receive TMC278 25 mg once daily up to Week 96.
Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
|
TMC278 25 mg tablet will be administered once daily.
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
他の名前:
|
|
実験的:TMC278 75 mg
Participants will receive TMC278 75 mg once daily up to Week 144.
Later on, participants will receive TMC278 25 mg once daily up to Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
他の名前:
TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
|
|
実験的:TMC278 150 mg
Participants will receive TMC278 150 mg once daily up to Week 96.
Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
他の名前:
TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
|
|
アクティブコンパレータ:Efavirenz
Participants will receive efavirenz 600 mg once daily up to Week 96.
Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
他の名前:
Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Virologic Response at Week 48 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
時間枠:Week 48
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 48
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
時間枠:Week 96
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 96
|
|
Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
時間枠:Week 96
|
The analysis is based on the last observed viral load data within the Week 96 window.
Virologic response is defined as a viral load less than 50 copies/mL.
Missing viral load was considered as non-response.
|
Week 96
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
時間枠:Week 240
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 240
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
時間枠:Week 240
|
The analysis is based on the last observed viral load data within the Week 240 window.
Virologic response is defined as a viral load less than 50 copies/mL.
Missing viral load was considered as non-response.
|
Week 240
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 400 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
時間枠:Week 240
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 240
|
|
Change From Baseline in CD4+ Cell Count (Absolute) at Week 96
時間枠:Baseline (Day 1 of Week 0) to Week 96
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 96
|
|
Change From Baseline in CD4+ Cell Count (Relative) at Week 96
時間枠:Baseline (Day 1 of Week 0) to Week 96
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 96
|
|
Change From Baseline in CD4+ Cell Count (Absolute) at Week 240
時間枠:Baseline (Day 1 of Week 0) to Week 240
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 240
|
|
Change From Baseline in CD4+ Cell Count (Relative) at Week 240
時間枠:Baseline (Day 1 of week 0) to Week 240
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of week 0) to Week 240
|
|
Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure
時間枠:Week 240
|
Virologic failure for the resistance determinations was defined as a viral load greater than 0.5 log10 copies /mL above the nadir with a minimum of 500 copies/mL.
For this study, treatment-emergent mutations (for at least one treatment) are presented as Resistance associated mutation (RAMs): i) Non-nucleotide reverse transcriptase inhibitor (NNRTI) RAMs, ii) Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).
|
Week 240
|
|
Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) for TMC278
時間枠:Up to Week 96
|
For each participant, a single value for area under the plasma concentration-time curve from time of administration up to 24 hours post dosing (AUC24h) of TMC278 was estimated from a population pharmacokinetic model, based on all samples collected throughout the trial up to Week 96.
|
Up to Week 96
|
|
Trough Plasma Concentration (Ctrough) for TMC278
時間枠:Up to Week 96
|
For each participant, a single value for trough (i.e.
predose) plasma concentration (Ctrough) of TMC278 was estimated from a population pharmacokinetic model, based on samples collected throughout the trial up to Week 96.
|
Up to Week 96
|
|
Number of Participants With Virologic Response (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm, by Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) Quartiles
時間枠:Up to Week 96
|
Quartile 1, 2, 3 and 4 of AUC24h means the quartile with the lowest 25%, 26-50%, 51-75% and the highest 25% of AUC24h values, respectively, irrespective of the different doses of TMC278.
For each participant, a single value for area under the plasma concentration-time curve from time of administration up to 24 hours post dosing (AUC24h) of TMC278 was estimated from a population pharmacokinetic model, based on all samples collected throughout the trial up to Week 96.
Virologic response was calculated by time to loss of virologic response (TLOVR) algorithm.
|
Up to Week 96
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2005年6月1日
一次修了 (実際)
2011年12月1日
研究の完了 (実際)
2011年12月1日
試験登録日
最初に提出
2005年5月5日
QC基準を満たした最初の提出物
2005年5月5日
最初の投稿 (見積もり)
2005年5月6日
学習記録の更新
投稿された最後の更新 (見積もり)
2014年6月25日
QC基準を満たした最後の更新が送信されました
2014年6月11日
最終確認日
2014年6月1日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- RNAウイルス感染症
- ウイルス病
- 感染症
- 血液感染症
- 伝染病
- 性感染症、ウイルス
- 性感染症
- レンチウイルス感染症
- レトロウイルス感染症
- 免疫系疾患
- 遅いウイルス病
- HIV感染症
- 後天性免疫不全症候群
- 免疫不全症候群
- 薬理作用の分子機構
- 抗感染剤
- 抗ウイルス剤
- 核酸合成阻害剤
- 酵素阻害剤
- 抗HIV薬
- 抗レトロウイルス剤
- シトクロム P-450 酵素阻害剤
- シトクロム P-450 酵素誘導剤
- シトクロム P-450 CYP3A インデューサー
- シトクロム P-450 CYP2B6 インデューサー
- シトクロム P-450 CYP2C9 阻害剤
- シトクロム P-450 CYP2C19 阻害剤
- 逆転写酵素阻害剤
- エファビレンツ
- リルピビリン
その他の研究ID番号
- CR006760
- TMC278-C204 (その他の識別子:Tibotec Pharmaceuticals, Ireland)
- R278474-C204 (その他の識別子:Tibotec Pharmaceuticals, Ireland)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。